PAREXEL Launches Biologic Sample Lifecycle Management

PAREXEL International Corp. has launched its Biological Sample Lifecycle Management service designed to enable optimal use of human biological samples. The service aims to help biopharmaceutical clients to more efficiently manage their patient biological sample assets from informed consent and collection at site, through in-study laboratory analysis, data generation and future use. The offering combines PAREXEL’s laboratory logistics and genomic medicine services with BioFortis consent and sample tracking software.

In drug development, human biological samples are essential, particularly in areas such as personalized, precision and genomic medicine. The new offering will help clients maintain sample integrity, security and compliance with changing regulations and guidelines. The service also provides oversight of samples across the ecosystem of laboratories, biorepositories and research and development facilities.

“Today, biopharmaceutical companies are experiencing an increased demand to provide full visibility into the chain of custody and consent status of human samples throughout the entire lifecycle, which involves complex logistics and data flows,” said Sanjay Vyas, corporate vice president and global head, Clinical Trial Supplies and Logistics, PAREXEL. “With this new offering, PAREXEL is leveraging its wide range of expertise to help clients optimize sample management to meet this demand and ultimately accelerate clinical development cycles so new medicines can reach patients sooner.” “Today, biopharmaceutical companies are experiencing an increased demand to provide full visibility into the chain of custody and consent status of human samples throughout the entire lifecycle, which involves complex logistics and data flows,” said Sanjay Vyas, corporate vice president and global head, Clinical Trial Supplies and Logistics, PAREXEL. “With this new offering, PAREXEL is leveraging its wide range of expertise to help clients optimize sample management to meet this demand and ultimately accelerate clinical development cycles so new medicines can reach patients sooner.”